The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

Applied Therapeutics APLT announced that the FDA has issued a Complete Response Letter (CRL) for the new drug application ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...

Lenacapavir, an injectable PrEP taken twice a year, demonstrated 96% efficacy in preventing HIV infections in a global Phase ...

The exciting prospects of harnessing Africa's medicinal plants to solve health challenges, particularly future pandemics and ...

As Thanksgiving Travel Starts Up, Gas Prices are Their Lowest Since 2020 ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...

The process of government formation in Maharashtra is expected to get a boost after a crucial meeting between caretaker CM Eknath Shinde, Devendra Fadnavis, Ajit Pawar and Union minister Amit Shah ...